| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | Lipid HTO12 Basic information |
| Product Name: | Lipid HTO12 | | Synonyms: | Lipid HTO12;heptadecan-9-yl 8-((2-hydroxyethyl)(2-hydroxytetradecyl)amino)octanoate | | CAS: | 3047222-45-4 | | MF: | C41H83NO4 | | MW: | 654.1 | | EINECS: | | | Product Categories: | | | Mol File: | 3047222-45-4.mol |  |
| | Lipid HTO12 Chemical Properties |
| Boiling point | 703.061±45.00 °C(Press: 760.00 Torr)(predicted) | | density | 0.919±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | solubility | Ethanol: Soluble: =10 mg/ml | | pka | 14.735±0.20(predicted) |
| | Lipid HTO12 Usage And Synthesis |
| Description | Lipid HTO12 is an ionizable cationic lipid (pKa = 6.432) that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA in vitro and in vivo.1 LNPs containing lipid HTO12 and encapsulating adenine base editor mRNA targeting Pcsk9 reduce hepatic Pcsk9 levels in mice at a reduced ionizable lipid/total lipids-to-mRNA ratio than LNPs containing SM-102 (Item No. 33474).WARNING This product is not for human or veterinary use. | | References | [1] QIUBING CHEN. Minimizing the ratio of ionizable lipid in lipid nanoparticles for in vivo base editing.[J]. National Science Review, 2024, 11 6: nwae135. DOI: 10.1093/nsr/nwae135 |
| | Lipid HTO12 Preparation Products And Raw materials |
|